Accueil / Communiqués / Cedilla Therapeutics Expands Leadership Team with Appointment of Chief Human Resources Officer

Cedilla Therapeutics Expands Leadership Team with Appointment of Chief Human Resources Officer

Monday, February 4th 2019 at 1:00pm UTC

, a biotechnology company broadening the reach of small
molecule therapeutics by discovering and exploiting unique insights into
protein stability, today announced the appointment of a veteran
biopharma executive, Andrew Dawson, as chief human resources officer.
Dawson brings a wealth of experience in company growth and culture
development, as well as talent acquisition and coaching.

“We’re delighted to welcome Andrew to Cedilla as we continue to build
out our team and expand our capabilities in drug discovery and
development,” said Alexandra Glucksmann, Cedilla’s president and chief
executive officer. “He will play an integral role on our leadership

Dawson brings more than 20 years of global experience in human resources
across the biotech and pharmaceutical industries. He joins Cedilla after
having served in senior roles of increasing scope and responsibility at
Shire, Roche, Novartis, Eli Lilly and TripAdvisor. Most recently, he was
a senior vice president and head of human resources at Enzyvant, leading
the worldwide human resources function and serving as a member of the
executive leadership team. Dawson received his M.Sc. in human resources
management and development from the University of Salford in Manchester,

“It’s a joy to step into this role in a startup with such a welcoming
and supportive culture – and such a strong sense of mission to deliver
new classes of drugs to patients,” Dawson said. “I look forward to
helping guide Cedilla’s growth.”

About Cedilla Therapeutics

Cedilla Therapeutics is discovering and exploiting unique insights into
protein stability. Cedilla’s integrated, multi-faceted approach has the
potential to broaden the reach of small molecules by generating
therapeutics that degrade protein targets as their primary mechanism of
action. The approach harnesses intrinsic degradation pathways that are
upstream of ubiquitination. Cedilla is focused on destabilizing
oncoprotein targets using a product engine that is also applicable to
targets outside of oncology. Cedilla was launched in 2018 by Third Rock
Ventures and is based in Cambridge, Mass. For more information, please


Stephanie Simon
Ten Bridge Communications

Source: Cedilla Therapeutics

Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …